Affordable Hearing Aids: Impact of OTC Regulations on Medicare and Users

High costs have historically deterred many from purchasing hearing aids, with prescription devices averaging $2,694 per pair in 2026, and Original Medicare not covering these expenses. The introduction of the over-the-counter (OTC) hearing aid category by the FDA in 2022 aimed to enhance accessibility and affordability. Despite the absence of legislative changes to Medicare policies for hearing aids as of 2026, some Medicare Advantage plans provide limited coverage for these devices.

In response to growing demand for more affordable options, the FDA established an OTC category in October 2022 for adults with self-identified mild to moderate hearing loss. Not requiring a prescription or professional fitting, these devices have improved greatly in quality. By 2026, OTC models have significantly narrowed performance gaps with prescription hearing aids, offering features such as AI processing, Bluetooth streaming, and water resistance. However, these remain unsuitable for children, individuals with severe hearing loss, or those requiring complex care.

It's important to distinguish OTC hearing aids from Personal Sound Amplification Products (PSAPs), which are not designed for hearing-impaired users and lack medical device regulation. Recognizing signs of mild to moderate hearing loss—like difficulty in noisy places or frequent requests for repetition—can guide potential buyers. Where medical symptoms such as ear discharge or sudden hearing loss occur, consultation with a healthcare professional is advised before considering hearing aids.

The selection between self-fitting and preset OTC hearing aids can impact user experience. Self-fitting models undergo FDA clearance for safety and effectiveness, which audiologists recommend if the budget allows. Key considerations should include speech-in-noise performance assessed by independent testing, battery life, and Bluetooth capabilities, with most models now supporting both major phone platforms.

OTC hearing aids typically offer a trial period of 30 to 45 days, allowing users to evaluate both the product and brand customer service. Performance can vary significantly by model:

• Budget option: The MDHearing NEO XS starts at $297, featuring strong feedback cancellation and a generous trial period.
• Mid-range choice: The Elehear Beyond Pro, priced at $599, is a top-rated OTC device, while the Yeasound RIC800, at $699, ranks highly in independent testing.
• Long wear time: For extended use, the Jabra Enhance Select 500 offers a 24-hour battery life, making it highly recommended for consistent use.
• Premium with support: The Jabra Enhance Select 700, starting at $1,195, offers superior sound quality with remote audiologist support.
• Sound clarity: The Sony CRE-E10 excels in sound clarity, verified by independent testing.

Awareness and usage of hearing aids remain low, with only 25% of those needing aids having used them. The average delay in purchasing a hearing aid post-diagnosis is nine years, contributing to associated risks like depression and social isolation. The OTC category seeks to bridge the gap between diagnosis and intervention, with its offerings now aligning with this objective in 2026.